C12N 2760/18443
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2760/18443 (Viral genome or elements thereof as genetic vector) appears on 54 US grants and 82 published applications in this corpus.
Search patents in C12N- Granted patents
- 54
- Published applications
- 82
- Assignees
- 39
- Inventors
- 155
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 1 | 0 |
| 2005 | 0 | 2 |
| 2006 | 0 | 2 |
| 2007 | 0 | 1 |
| 2008 | 1 | 2 |
| 2009 | 2 | 0 |
| 2010 | 2 | 2 |
| 2011 | 1 | 3 |
| 2012 | 2 | 5 |
| 2013 | 0 | 6 |
| 2014 | 2 | 1 |
| 2015 | 4 | 5 |
| 2016 | 3 | 3 |
| 2017 | 5 | 7 |
| 2018 | 3 | 4 |
| 2019 | 6 | 7 |
| 2020 | 3 | 6 |
| 2021 | 6 | 7 |
| 2022 | 4 | 0 |
| 2023 | 3 | 10 |
| 2024 | 3 | 3 |
| 2025 | 0 | 2 |
| 2026 | 3 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Measles virus vaccine expressing SARS-CoV-2 protein(s)16 Jun 2026US 12,653,881 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases27 Jan 2026US 12,533,404 B2Centre National De La Recherche Scientifique
- Viral vectors for nuclear reprogramming20 Jan 2026US 12,529,073 B2Mayo Foundation for Medical Education and Research
- Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions10 Dec 2024US 12,163,150 B2Centre National De La Recherche Scientifique
- Coronavirus disease (COVID-19) vaccine7 May 2024US 11,975,067 B2Thomas Jefferson University
- Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases6 Aug 2026US 2026/0224687 A1Centre National De La Recherche Scientifique
- Viral vectors for nuclear reprogramming14 May 2026US 2026/0132420 A1Mayor Foundation for Medical Education and Research
- Immunogenic compositions for epstein-barr virus proteins30 Apr 2026US 2026/0115277 A1Merck Sharp & Dohme Corp.
- Immunogenic compositions for herpes simplex virus proteins9 Oct 2025US 2025/0312441 A1Merck Sharp & Dohme Corp.
- Novel usage of oncolytic gene-modified measles virus19 Jun 2025US 2025/0195634 A1The University of Tokyo
Most cited
By later US patents
- cDNA corresponding to the antigenome of nonsegmented negative stranded RNA viruses and process for the production of such viruses40US 7,993,924 B2Crucell Switzerland AG · 2011
- Dengue and West Nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications13US 7,556,812 B2Centre National De La Recherche Scientifique · 2009
- Chromatography based purification strategies for viruses10US 10,894,079 B2Themis Bioscience GmbH · 2021
- Infectious recombinant paramyxovirus from antigenomic cDNA10US 7,851,214 B2Crucell Switzerland AG · 2010
- Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae infection10US 8,337,857 B2Centre National De La Recherche Scientifique · 2012